FDA approves first once-weekly drug treatment regimen for hemophilia
Patients suffering from hemophilia received a "meaningful" advancement on Friday when federal regulators approved the first ...
Pfizer wins FDA approval for hemophilia B drug that will be first once-weekly treatment
The new drug would allow patients to produce the needed clotting protein for an extended period, reducing the need for ...
Medscape2d
FDA Approves Pfizer's Hympavzi for Hemophilia A, B
The monoclonal antibody is the first non-factor, once-weekly treatment approved in the United States for hemophilia B.
Medpage Today on MSN2d
Marstacimab Gets FDA Nod for Hemophilia A or B Without Inhibitors
The FDA approved marstacimab (Hympavzi) for routine prophylaxis to prevent or reduce bleeding episodes in adults and ...
Pfizer’s Hympavzi Approved for Treatment of Certain Types of Hemophilia
The FDA approved Pfizer’s Hympavzi, which can be an alternative to intravenous infusions often administered multiple times a ...
The Financial Express5h
USFDA gives nod to Pfizer’s drug therapy for patients with Hemophilia
The FDA granted the approval of Hympavzi to Pfizer Inc.
Daily2h
Pfizer Hemophilia drug Hympavzi Receives USFDA Approval
Pfizer announced on Friday that the U.S. Food and Drug Administration has granted approval for its once-weekly injection ...
FiercePharma2d
Pfizer doubles down with its 2nd FDA hemophilia approval in 6 months
Six months after scoring FDA approval for hemophilia B gene therapy Beqvez, Pf | For the second time in six months, the FDA ...
The American Journal of Managed Care2d
FDA Approves Marstacimab, First Weekly Sub-Q Option for Hemophilia B
The American Journal of Managed Care provides insights into the latest news and research in managed care across multimedia ...
U.S. FDA Approves Pfizer’s HYMPAVZI™ (marstacimab-hncq) for the Treatment of Adults and Adolescents with Hemophilia A or B Without Inhibitors
Pfizer Inc. (NYSE: PFE) announced today that the U.S. Food and Drug Administration (FDA) has approved HYMPAVZIâ„¢ ...
The Pharma Letter1d
FDA approves new treatment for hemophilia A or B
The US Food and Drug Administration (FDA) on Friday approved US pharma giant Pfizer’s Hympavzi (marstacimab-hncq) for routine ...
Managed Healthcare Executive2d
FDA Approves Hympavzi for Hemophilia A and B
The FDA approved Pfizer’s Hympavzi (marstacimab-hncq) to prevent or reduce the frequency of bleeding episodes in patients age ...